From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
“Lilly scientists delivered the first doses of our potential #COVID19 antibody treatment, flown to hospitals in several U.S. cities to start the world’s first human study of this kind of therapy to fight COVID infections.” @lillypad First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with […]
UArizona Pharmacy Researcher Identifies Compounds That May Lead to Potential Treatments for COVID-19
Findings on compounds that block SARS-COV-2 viral replication may offer a promising starting point for further development of treatments to address the ongoing, devastating novel coronavirus pandemic.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are: Merck to acquire Themis Bioscience, a company focused on […]
In a new study appearing in the journal BMC Immunology, lead researcher Milene Peterson along with a team of researchers including Stephen Johnston, all in the Biodesign Center for Innovations in Medicine, took a look at the efficacy of personal vaccines versus shared vaccines, which target mutations shared by the majority of individuals with a […]
- Digital RESI – Three Day Conference
- 06/08/2020 - 06/10/2020
- NCCN Oncology Policy Summit: Accelerating Advances in Cancer Care Research: A Look Back at the 21st Century Cures Act in 2020
- AZBioPEERS: Building a Company that is Investment Ready
- Real World Evidence - Meet the future with confidence.
- AZBioPEERS: What is my company worth? Establishing a valuation